Renal denervation attenuates progression of atherosclerosis in Apolipoprotein E-deficient mice independent of blood pressure lowering

Hypertension

Volumn 65, Issue 4, 2015, Pages 758-765

  Wang, Hui ^a   Wang, Jintao ^a   Guo, Chiao ^a   Luo, Wei ^a   Kleiman, Kyle ^a   Eitzman, Daniel T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

atherosclerosis; hypertension; oxidative stress; sympathetic nervous system

Indexed keywords

8 ISOPROSTANE; ALDOSTERONE; ANGIOTENSIN II; APOLIPOPROTEIN E; CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NORADRENALIN; RENIN; TRIACYLGLYCEROL; 8-EPI-PROSTAGLANDIN F2ALPHA; PROSTAGLANDIN F2 ALPHA;

ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BRACHIOCEPHALIC TRUNK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; KIDNEY DENERVATION; LIMIT OF DETECTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SHAM PROCEDURE; SMOOTH MUSCLE FIBER; SYMPATHETIC NERVE CELL; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN DIET; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BLOOD PRESSURE MEASUREMENT; DEFICIENCY; DISEASE MODEL; HYPERTENSION; KIDNEY; PATHOPHYSIOLOGY; PROCEDURES; SYMPATHECTOMY;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE DETERMINATION; CHEMOKINE CCL2; DINOPROST; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYPERTENSION; KIDNEY; MALE; MICE; OXIDATIVE STRESS; SYMPATHECTOMY;

EID: 84929130005     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04648     Document Type: Article

References (24)

1. Lüscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level?. Eur Heart J. 2014; 35: 1706-1711. doi: 10.1093/eurheartj/ehu195
2. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370: 1393-1401. doi: 10.1056/NEJMoa1402670
3. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011; 123: 1940-1946. doi: 10.1161/CIRCULATIONAHA.110.991869
4. Nakagawa T, Hasegawa Y, Uekawa K, Ma M, Katayama T, Sueta D, Toyama K, Kataoka K, Koibuchi N, Maeda M, Kuratsu J, Kim-Mitsuyama S. Renal denervation prevents stroke and brain injury via attenuation of oxidative stress in hypertensive rats. J Am Heart Assoc. 2013; 2: e000375. doi: 10.1161/JAHA.113.000375
5. King AJ, Osborn JW, Fink GD. Splanchnic circulation is a critical neural target in angiotensin II salt hypertension in rats. Hypertension. 2007; 50: 547-556. doi: 10.1161/HYPERTENSIONAHA.107.090696
6. Zhang J, Villacorta L, Chang L, Fan Z, Hamblin M, Zhu T, Chen CS, Cole MP, Schopfer FJ, Deng CX, Garcia-Barrio MT, Feng YH, Freeman BA, Chen YE. Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res. 2010; 107: 540-548. doi: 10.1161/CIRCRESAHA.110.218404
7. Wang H, Luo W, Wang J, Guo C, Wolffe SL, Wang J, Sun EB, Bradley KN, Campbell AD, Eitzman DT. Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease. Br J Haematol. 2013; 162: 120-129. doi: 10.1111/bjh.12342
8. Wang H, Luo W, Wang J, Guo C, Wang X, Wolffe SL, Bodary PF, Eitzman DT. Obesity-induced endothelial dysfunction is prevented by deficiency of P-selectin glycoprotein ligand-1. Diabetes. 2012; 61: 3219-3227. doi: 10.2337/db12-0162
9. Jänig W, Häbler HJ. Specificity in the organization of the autonomic nervous system: a basis for precise neural regulation of homeostatic and protective body functions. Prog Brain Res. 2000; 122: 351-367
10. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev. 2010; 90: 513-557. doi: 10.1152/physrev.00007.2009
11. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953; 152: 1501-1504
12. Kopp UC. Neural Control of Renal Function. San Rafael, CA: Morgan & Clayppol Life Sciences; 2011
13. Johns EJ, Kopp UC, DiBona GF. Neural control of renal function. Compr Physiol. 2011; 1: 731-767. doi: 10.1002/cphy.c100043
14. Mahfoud F, Lüscher TF, Andersson B, et al; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013; 34: 2149-2157. doi: 10.1093/eurheartj/eht154
15. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012; 59: 901-909. doi: 10.1016/j. jacc.2011.11.034
16. Huang WC, Fang TC, Cheng JT. Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats. Hypertension. 1998; 32: 249-254
17. Katayama T, Sueta D, Kataoka K, Hasegawa Y, Koibuchi N, Toyama K, Uekawa K, Mingjie M, Nakagawa T, Maeda M, Ogawa H, Kim-Mitsuyama S. Long-term renal denervation normalizes disrupted blood pressure circadian rhythm and ameliorates cardiovascular injury in a rat model of metabolic syndrome. J Am Heart Assoc. 2013; 2: e000197. doi: 10.1161/JAHA.113.000197
18. Zhang ZH, Yang K, Jiang FL, Zeng LX, Jiang WH, Wang XY. The effects of catheter-based radiofrequency renal denervation on renal function and renal artery structure in patients with resistant hypertension. J Clin Hypertens (Greenwich). 2014; 16: 599-605. doi: 10.1111/jch.12367
19. Luo W, Wang H, Ohman MK, Guo C, Shi K, Wang J, Eitzman DT. P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis. 2012; 220: 110-117. doi: 10.1016/j. atherosclerosis.2011.10.012
20. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 2005; 46: 1135-1139. doi: 10.1161/01.HYP.0000184640.81730.22
21. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002; 105: 2212-2216
22. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003; 41: 955-963
23. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004; 109: 2213-2220. doi: 10.1161/01. CIR.0000127949.05756.9D
24. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006; 17: 1362-1372. doi: 10.1681/ASN.2005111196